4D Molecular Therapeutics Inc To Discuss Interim Data Transcript
Hello ladies and gentlemen, thank you for standing by and welcome to our investor webcast today. As a reminder, today's call is being recorded. With that, I will hand the call over to Julian Pye, head of investor relations, who will make introductory comments.
Morning and thank you for joining our webcast to discuss interim phase 1 data from our arrow trial in cystic fibrosis.
Before we begin, I encourage everyone to visit our investor relations website where you can find a press release describing this update.
A recording of this webcast and presentation materials will also be accessible on the website after the completion of this call.
We remind you here we may be making forward-looking statements. For further details, you can visit our website or our SEC filings.
On the call today with prepared remarks will be Dr. David Kern, our co-founder and CEO, Dr. Jennifer Taylor Kawser from National Jewish Health and lead principal
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
